Video recording & full transcript (translatable in 40 languages) now available for the Pulmonary Hypertension Expert Patient Academy (PHEPA) joint Alliance for Pulmonary Hypertension and PHA Europe project
LINK TO VIDEO TRANSCRIPT Can be translated in 40 languges, check orange button on bottom of page Gergely Meszaros: Good evening and good afternoon to everyone. Welcome to this webinar introducing the Pulmonary Hypertension Expert Patient Academy (PHEPA). I’m delighted to present this new initiative. When ERN-LUNG, the European Reference…
Read More
United Therapeutics announces results for its Phase 3 ADVANCE OUTCOMES study on ralenipag for pulmonary arterial hypertension, March 2, 2026
United Therapeutics has announced promising results from its pivotal Phase 3 ADVANCE OUTCOMES study of ralinepag, a new oral treatment for pulmonary arterial hypertension (PAH). Ralinepag is a highly selective prostacyclin (IP) receptor agonist that works through multiple pathways — vasodilatory, anti-proliferative, and anti-inflammatory. It is taken once daily orally,…
Read More
2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026
A consensus document featuring 10 statements, the main focus of which was the use of parenteral prostanoids, was developed by eight experts in pulmonary arterial hypertension during in-person and web-based meetings. Forty-six Italian physicians were invited online to rate each statement, indicating their agreement, neutrality or disagreement. These consensus statements…
Read MoreNippon Shinyaku reports progress on trials on NS-863 targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Nippon Shinyaku recently reported progress on two Phase 2 trials of its oral candidate NS-863, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), both serious cardiopulmonary conditions with high unmet need. By advancing NS-863 across two related indications, the company is signaling a deeper…
Read MoreComparing survival and comorbidities between two sub-groups of pulmonary arterial hypertension from the Spanish REHAP Registry, Rheumatology (Oxford), February 27, 2026
A retrospective study based on data from the Spanish pulmonary arterial hypertension Registry (REHAP) set out to compare the demographic and clinical profiles, comorbidity burden, and survival rates of patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) against those with idiopathic pulmonary arterial hypertension (IPAH). The study, covering the…
Read More
Tenax Therapeutics extends long-term study of oral levosimendan (TNX-103) in pulmonary hypertension with preserved ejection fraction (HFpEF) patients, February 2026
Tenax Therapeutics is conducting a long-term open-label extension study of TNX-103, an oral formulation of levosimendan, in patients with pulmonary hypertension associated with heart failure and preserved Ejection Fraction (HFpEF), Group 2 of the World Health Organisation classification. In its intravenous form TNX-103 is a drug authorized for use in…
Read More
GSK set to buy 35Pharma, currently investigating drug for pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction, February 25, 2026
GSK, a UK pharmaceutical multinational, has agreed to acquire 35Pharma, a private Canadian clinical-stage biopharmaceutical company, for $950m in cash. The transaction will provide GSK with full ownership of 35Pharma and its lead investigational medicine, HS235, an activin receptor signalling inhibitor currently positioned for studies in pulmonary arterial hypertension (PAH)…
Read More
New edition of the German pulmonary hypertension association ph e.v. magasine RUNDBRIEF, February 2026
Here is the AI translation of the index. Patient Community & Events Regional Association Updates (Landesverbände) Reports from local pulmonay hypertension chapters across Germany, covering Baden-Württemberg, Bavaria, Berlin/Brandenburg/Mecklenburg-Vorpommern, Hamburg/Schleswig-Holstein, Hesse, North Rhine-Westphalia, Saxony, and Saarland/Rhineland-Palatinate (pp. 16–33), plus a directory of regional leaders (p. 33). Medical & Scientific Topics Practical…
Read More
Defying Limits: Eight transplant recipients accompanied by medical team from Vienna, climb Aconcagua (6,961 meters), in Argentina – the highest peak in the Americas!
AI translation of article on MedUni, Vienna, Austria news, available in German at this link Vienna, February 25, 2026 – In January 2026, eight lung transplant recipients and their companions from five nations, together with a medical team from MedUni Vienna, climbed Aconcagua (6,961 meters) in Argentina – the highest…
Read MoreResults of the PROSERA study for seralutinib in pulmonary arterial hypertension released by Gossamer Bio on February 23, 2026
The PROSERA study for seralutinib in pulmonary arterial hypertension findings were released yesterday and report that it did not meet its primary endpoint in the full population. It appears that unexpected placebo results in some geographical areas may have been responsible for this happening. While this is disappointing news for…
Read More
The UK’s pulmonary hypertension association free resource of the month is a four week program to address depression
Developed by psychologists, and supported by the UK’s pulmonary hyeprtension association, PHA UK, this four-week programme consists of a series of workbooks based on Cognitive Behavioural Therapy (CBT), to help patients change their thinking habits and behaviours. Find our more at this link on the PHA UK website
Read More
Report on access to sotatercept in the UK and Scotland by the UK pulmonary hypertension association, PHA UK
SCOTLAND: It was announced last week (9th February) that sotatercept, the ‘first in class’ pulmonary arterial hypertension treatment, will not be commissioned for use by NHS Scotland at this stage. Our fellow patient advocates at the PHA UK note that whilst this is disappointing news initial refusal is common for…
Read More
Ensuring cultural relevance in pulmonary arterial hypertension QOL questionnaire adaptation: the Thai emPHasis-10 case, Journal of Patient-Reported Outcomes, February 20, 2026
The emPHasis-10 questionnaire is a specialized tool for assessing health-related quality of life in pulmonary arterial hypertension patients. A comprehensive validation process was undertaken by researchers in Thailand including forward-backward translation, expert content validity assessment using Item-Objective Congruence (IOC) index by five specialists, and reliability testing with 20 Thai PAH…
Read MoreThe Alliance for Pulmonary Hypertension and PHA Europe launch joint project for a European Pulmonary Hypertension Expert Patient Academy! Join us for a live webinar on February 27 to learn more!
In honour of Rare Disease Day we’re excited to unveil the Pulmonary Hypertension Expert Patient Academy (PHEPA) a groundbreaking collaboration between Alliance for Pulmonary Hypertension and PHA Europe, officially endorsed by the European Reference Network for Rare Respiratory Diseases (ERN-LUNG), on February 27th. Download the slides This webinar showcased how…
Read More
“Ask a PH Doc”, a new PHA Canada program to connect the pulmonary hypertension community with Canadian specialists
“Ask a PH Doc” is a new program designed by the Canadian pulmonary hypertension association PHA Canada to connect the pulmonary hypertension community with Canadian specialists. One can submit general questions about diagnosis, medications, lifestyle, mental health, caregiving, and navigating the healthcare system in Canada. Every question receives a response,…
Read More
Living with Chronic Lung Allograft Dysfunction (CLAD), a live webinar organised by ESOT, the European Society for Organ Transplant, March 18, 2026
Not to be missed! This live webinar organised by the European Society for Organ Transplant aims to provide an update on the burden of Chronic Lung Allograft Dysfunction (CLAD), emphasizing the patient’s perspective and most important challenges living with CLAD. The webinar will cover respiratory rehabilitation and palliative care measures,…
Read More
How to explain the complexities of pulmonary hypertension to others, Jolie Lizana, Pulmonary Hypertension News, January 30, 2026
A powerful piece by patient advocate Jolie Lizana recently published on Pulmonary Hypertension News tackles a crucial but often overlooked challenge: how to explain pulmonary hypertension to others when it’s such a complex, invisible disease. Writing from her own 12-year journey living with pulmonary hypertension and heart failure, Lizana realized…
Read MoreCereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease
Cereno Scientific has expanded the development focus of its oral HDAC inhibitor CS014 to include pulmonary hypertension associated with interstitial lung disease (PH-ILD), a severe condition with very limited treatment options and high unmet medical need. Originally developed for idiopathic pulmonary fibrosis (IPF), CS014 targets shared disease mechanisms including vascular…
Read More
PHA Canada welcomes a new volunteer “Knowledge Philanthropist”, Lisa Harder, in its pulmonary hypertension patient support team
Lisa Harder is PHA Canada’s newest Knowledge Philanthropist. These are specialized volunteers help the organization fulfill its mission. Each Knowledge Philanthropist serves the pulmonary hypertension community in their own way. Depending on their professional background, they develop resources, content from current research projects, help raise awareness, and more! Lisa brings…
Read More
Heart and lung machine (ECMO) boosts survival for pregnant women with pulmonary arterial hypertension and pregnancy in a case series, Pulmonary Hypertension News, February 2, 2026
Pulmonary Hypertension News published a report on February 2, 2026, about a case series and literature review found that ECMO (extracorporeal membrane oxygenation)—a life-support machine that temporarily replaces heart and lung function—significantly improves survival in pregnant women with severe pulmonary arterial hypertension (PAH). The study documented five cases where the…
Read MoreSomething went wrong. Please refresh the page and/or try again.
Archive (974) News (701) Save the date (5)
AI (3) America (17) Asia (13) biomarkers (2) BMPR2 (3) Colombia (3) CTEPH (7) Deutsch (3) diagnosis (5) diagnostics (3) ELF (3) EMA (3) English (4) epoprostenol (2) ERS (3) ESOT (4) Europe (34) Francais (9) genetics (4) genetic testing (2) German (4) Germany (3) health technology assessment (3) Hipertensión Pulmonar (2) HTA (3) HTAP (5) Italiano (6) Latinamerica (14) Lungenhochdruck (3) nutrition (2) PAH (9) PAHSSc (6) patient engagement (2) PH (3) PHA (11) PHA UK (8) PROMs (2) Pulmonale Hypertensie (2) remote monitoring (4) RHC (3) right heart catheterisation (3) risk assessment (2) scleroderma (3) Spain (3) Turkish (7)